The rapid expansion of the gene editing market has created a powerful, parallel industry dedicated to contract research, development, and manufacturing (CRO/CDMO). Because developing gene therapies is exceptionally complex and capital-intensive, most small to mid-sized biotech companies rely heavily on these specialized third-party organizations for services like vector manufacturing,...